WASHINGTON & SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)--California Life Sciences Association (CLSA), the trade association representing California’s innovative life sciences sector, today applauded the U.S. House passage of H.R. 6378, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018, legislation which is critical for safeguarding our nation’s biodefense and pandemic preparedness enterprise. The bill now awaits U.S. Senate action. The following statement can be attributed to Sara Radcliffe, President & CEO, CLSA:
“California Life Sciences Association (CLSA) applauds yesterday’s U.S. House passage of H.R. 6378, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018, legislation that will strengthen and improve our national preparedness and response for public health emergencies and accelerate medical countermeasure R&D. The recent Ebola and Zika outbreaks and ongoing threats from terrorist organizations like ISIS have repeatedly exposed our nation’s continued vulnerability to bioterror and pandemic threats, demonstrating the need for robust biodefense preparedness.
“CLSA commends the leadership of Reps. Anna G. Eshoo (D-Palo Alto) and Susan W. Brooks (R-Ind.) for their careful and dedicated work on this important issue. On behalf of California’s life sciences innovators, a sector with over 3,000 firms employing 300,000 people, we urge the U.S. Senate’s swift action on this critical legislation, which will bolster our nation’s biodefense preparedness and response capabilities.”
Click here to view CLSA’s support letter and learn more about the bill.
- Learn more about the California life sciences industry
- View CLSA’s Legislative Action Center
- Watch CLSA’s Faces of California Biomedical Innovation Web Series
- View CLSA’s Advocacy Priorities
- View upcoming CLSA events
About California Life Sciences Association (CLSA)
California Life Sciences Association (CLSA) is the state’s largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.